Health News Releases

  • Today September 11
May 22, 14:30
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology,
New, state of the art, clinical trial unit at QPS Miami in South Miami, Florida USA. (Photo: Busines
May 22, 13:40
QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials
QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical
May 22, 11:35
Leading Pharmaceutical Company Selects Kinaxis to Cure Supply Chain Headaches
Kinaxis (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54001339&newsitemid=20240521977758&lan=en-US&anchor=Kinaxis&index=1&md5=5f9eae6c7e7cdf798bb35930e
(Photo: Business Wire)
May 22, 11:00
Carestream Introduces Image Suite MR 10 Software to Enhance Imaging Experience for CR and DR Imaging Systems
Carestream launches its Image Suite MR 10 Software to help deliver a boost to productivity and efficiency while enabling a more user-friendly imaging experience for radiographers. Carestream’s Imag
Benjamin Binot, P&G Europe Oral Care Senior Vice President, announcing the launch of the Disability
May 16, 16:44
New Award Programme From Oral-B and the International Association for Disability and Oral Health (iADH) Champions Disability Positive Dental Practices Across Europe
Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In
Brain organoids on electrodes (Photo: Business Wire)
May 16, 16:00
FinalSpark Launches the First Remote Research Platform Using Human Neurons for Biocomputing
FinalSpark, a pioneering Swiss biocomputing startup, has launched the first-ever online platform enabling global researchers to conduct experiments remotely on biological neurons in vitro. The platfor
May 16, 14:20
Optiscan Signs Know-How Agreement with Mayo Clinic
Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital conf
Carestream CEO Todd Clegg (Photo: Business Wire)
May 16, 13:09
Todd Clegg Named Carestream’s Chief Executive Officer
Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective i
May 16, 10:03
MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead as
May 15, 10:30
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
Takeda (TSE: 4502/NYSE:TAK) (https://www.takeda.com/investors/overview/) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the Am
May 14, 14:10
GRAMINEX®, L.L.C. Final Publication of a Peer Reviewed Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence in Current Urology.
Graminex®, L.L.C. is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology. The
May 14, 09:55
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53983823&newsitemid=20240510475155&lan=en-US&anchor=Takeda&index=1&md5=4a403ee030780c54b5ebde46e786f5
May 13, 10:20
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Manage
May 10, 14:55
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53978747&newsitemid=20240508878785&lan=en-US&anchor=BeiGene&index=1&md5=289a1210b11d33d3f6dbd570f8e
May 09, 15:40
LC-Plasma-based Vaccine Research Selected for SCARDA Project
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis str
May 09, 13:55
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML
A groundbreaking research study,[1] sequencing DNA samples from the Pre-MEASURE study[2] strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood
May 07, 14:35
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic derm
May 07, 11:30
Parse Biosciences Launches Single Cell Immune Profiling Products
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR pro
May 03, 10:35
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 bi
WHOOP announces significant global expansion, appoints new senior leadership. Continues “Free Trials
May 01, 12:55
WHOOP Announces Significant Global Expansion, Appoints New Senior Leadership
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F&esheet=53961244&newsitemid=20240429085870&lan=en-US&anchor=WHOOP&index=1&md5=208ea6634cca605d44e019265ce45daf)
April 28, 13:10
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended
April 28, 11:40
CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO
April 25, 17:05
Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers
Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts. As detailed in its complaint, Exergen’s lawsuit i
April 25, 14:55
Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation provi
April 24, 14:34
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. · Record net sales of 1.071 billion USD in the first qu
Rubedo Life Sciences scientists (Photo: Business Wire)
April 24, 10:10
Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging
Rubedo Life Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rubedolife.com%2F&esheet=53939040&newsitemid=20240423657886&lan=en-US&anchor=Rubedo+Life+Sciences&index=1&md
April 24, 09:30
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA tec
April 23, 16:50
AI Medical Service Inc. Signs Joint Research Agreement with Mahidol University in Thailand
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, signed a joint research agreement with Mahidol University in Thailand (herein
High power UV-C LED (Graphic: Business Wire)
April 23, 15:45
Toyoda Gosei Develops UV-C LED with World-Class Light Output
Toyoda Gosei Co., Ltd. (TOKYO:7282) has developed deep ultraviolet (UV-C) LEDs with light output that is among the highest in the world.[1] UV-C is used in disinfection as it destroys viral and bacter
April 23, 09:45
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
Rubedo Life Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rubedolife.com%2F&esheet=53939039&newsitemid=20240422384739&lan=en-US&anchor=Rubedo+Life+Sciences&index=1&md
Learn more about the economic benefits of investing in adult immunisation programmes in a new study
April 18, 15:40
The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
A new report published today reveals that adult vaccination programmes can return up to 19 times their initial investment when the full spectrum of economic and societal benefits is valued. The 19x re
April 18, 14:15
Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile
Masimo (https://www.masimo.com/en-us/) (NASDAQ: MASI) today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patien
April 18, 08:00
INB Korea Ltd removes the bubble of the price on air sterilizer, cutting the price by 70% , NEW ‘UPPERVIOLET ODEO’ product is launched
INB Korea Ltd, the manufacturer of ‘viruskiller’, a K- air purifier and sterilizer product in Korea that exported 20 million dollar to 53 countries during the COVID19 outbreak, announced on the 17th o
Left to right: Tony Dos Santos, Founder | Maria Zaccardo, Co-founder | Sanjay D. Goorachurn, CEO (Ph
April 17, 09:57
A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer
Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos a
April 17, 09:15
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clin
JB Agnus, Chief Business Officer, KBI Biopharma, Inc. (Photo: Business Wire)
April 16, 11:40
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief
April 12, 15:00
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply
April 09, 14:28
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Ferring today published its 2023 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2024%2F04%2FFerring-Pharmaceutic
April 09, 13:19
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53923546&newsitemid=20240408059362&lan=en-US&anchor=TSE%3A4502%2FNYSE%
April 09, 12:05
AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine
PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients
April 09, 11:30
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the p
April 04, 15:10
Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin
Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500000-square-foo
April 04, 14:35
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.conformation-x.com&esheet=53921384&newsitemid=20240403623298&lan=en-US&anchor=Conformation-X+Ther
April 03, 15:20
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the tra
Peter Carbone, KBI Biopharma Chief Quality Officer (Photo: Business Wire)
April 02, 13:50
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Of
March 29, 10:55
Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report (https://cts.businesswi
March 28, 10:30
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Sharehold
March 27, 13:30
Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
Medisca, a global leader in personalized medicine and pharmaceutical supply chain solutions, proudly announces the opening of the Medisca MAZ Lab (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
March 26, 11:50
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative techno
March 22, 11:00
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&newsitemid=20240319911372&lan=en-US&anchor=TSE%3A4502%2FNYSE%
25 per page50 per page75 per page100 per page